BioHealth News
Previous BHCR Crab Trap Winner LifeSprout Completes CE Mark Submission for Lumina™, a Next-Generation Aesthetics Dermal Filler
BALTIMORE, Jan. 23, 2025 /PRNewswire/ -- LifeSprout, a privately held regenerative medicine company founded with technology licensed from Johns Hopkins University, today announced it has filed for…
Read MoreSenseonics Completes CE Mark Submission for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor
GERMANTOWN, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing…
Read MoreInvesting in BioHealth: Dr. Deborah Hemingway on Building Maryland’s Commercialization Hub on BioTalk
[vc_row type="in_container" full_screen_row_position="middle" column_margin="default" column_direction="default" column_direction_tablet="default" column_direction_phone="default" scene_position="center" text_color="dark" text_align="left" row_border_radius="none" row_border_radius_applies="bg" overlay_strength="0.3" gradient_direction="left_to_right" shape_divider_position="bottom" bg_image_animation="none"][vc_column column_padding="no-extra-padding" column_padding_tablet="inherit" column_padding_phone="inherit" column_padding_position="all" column_element_spacing="default" background_color_opacity="1" background_hover_color_opacity="1" column_shadow="none"…
Read MoreAPT – SCOPE Summit 2025: Emmes’ Peter Ronco on Small Biopharma & Clinical Trial Partnerships
In an interview with ACT Associate Editor Don Tracy, Peter Ronco, CEO, Emmes, discusses the "Choosing the Right Allies: Ensuring Clinical Trial Success for…
Read MoreChildren’s National Hospital and Virginia Tech Expand Research Partnership to Advance Pediatric Health
Newswise — Children’s National Hospital and Virginia Tech are expanding their research partnership, building on a successful collaboration established in 2019. This partnership will…
Read MoreVanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
WASHINGTON and SAN DIEGO, Feb. 3, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, global license agreement for the development…
Read MoreSupernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous…
Read MoreUnited Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
Over 100,000 patients in the United States have IPF, with only two approved therapies available that only slow the course of disease progression Top line data…
Read MoreUnited Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug…
Read MoreMCEDC: Nearly $3 Billion Invested in Montgomery County, Maryland Companies in 2024
MONTGOMERY COUNTY, Md. — Businesses in Maryland’s Montgomery County experienced a surge in investment funding in 2024. Mergers and acquisitions, venture capital and private…
Read MoreGeorgetown Entrepreneurs Win $150,000 in Prizes During Annual ‘Bark Tank’ Pitch Competition
Eight student teams on a mission to make a positive impact on society presented their startup ideas to a panel of expert judges during…
Read MoreTheradaptive’s OsteoAdapt™ SP Launches in Maryland with First Patient Dosed and $1 Million MSCRF Grant Support
FREDERICK, Md., Jan. 30, 2025 /PRNewswire-PRWeb/ -- Theradaptive, a Maryland-based, privately held, clinical-stage biologics company, today announced the initiation of patient dosing in Maryland for the ongoing OASIS Phase I/II clinical…
Read MoreMaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
ROCKVILLE, Md., Jan. 30, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing solutions to advance the…
Read Morecitybiz: ETC Baltimore Marks Milestone with Opening of Venture Hub at Connect Labs Baltimore
ETC Baltimore, dedicated to elevating Baltimore as a national leader in tech startups, announces the opening of its inaugural ETC Venture Hub at Connect Labs Baltimore in the newly…
Read MoreExciting Opportunities for BioHealth Companies in Montgomery County, MD in 2025 and Beyond
For the second year in a row, the BioHealth Capital Region (BHCR) has been ranked as a Top 3 BioCluster Hub by Genetic Engineering…
Read More